TABLE 2.
COVID‐19 progression to severe or critical degree and deaths during follow‐up compared to the control NmAbs untreated cohort
| Cohort of patients treated with NmAbs (n = 88) | Control cohort without NmAbs treatment (n = 575) | ||
|---|---|---|---|
| Progression to severe/critical COVID‐19 | Deaths attributed to COVID‐19 | Deaths attributed to COVID‐19 | |
| Total patients, n (%) | 15/88 (17) | 7/88 (8) | ND |
| Total “remdesivir/CP‐naïve” patients, n (%) | 6/69 (9) | 4/69 (6) | 93/575 (16) |
| Underlying disease at baseline, n (%) | |||
| Lymphoma | 5/30 (17) | 2/30 (7) | 22/114 (19) |
| Acute leukemia | 3/17 (18) | 1/17 (6) | 14/87 (16) |
| Multiple myeloma | 5/17 (29) | 2/17 (12) | 16/88 (18) |
| Chronic lymphocytic leukemia | 1/12 (8) | 1/12 (8) | 21/88 (24) |
| Myeloproliferative neoplasias | 0/4 (0) | 0/4 (0) | 6/57 (11) |
| Chronic myeloid leukemia | 0/2 (0) | 0/2 (0) | 1/53 (2) |
| Myelodysplastic syndrome | 0/2 (0) | 0/2 (0) | 9/34 (27) |
| Other hematological diseases | 1/4 (25) | 1/4 (25) | 4/54 (7) |
| Last hematological therapy prior to COVID‐19, n (%) | |||
| Anti‐CD20 monoclonal antibody | 4/28 (14) | 3/28 (11) | ND |
| Induction/reinduction of AL | 3/5 (60) | 1/5 (20) | ND |
| Autologous SCT | 2/8 (25) | 1/8 (13) | ND |
| Allogeneic SCT | 0/6 (0) | 0/6 (0) | ND |
| RD | 1/1 (100) | 0/1 (0) | ND |
| DRD | 1/4 (25) | 1/4 (25) | ND |
| Corticosteroids | 2/4 (50) | 1/4 (25) | ND |
| BV‐CHP | 1/1 (100) | 0/1 (0) | ND |
| VTD | 1/2 (50) | 0/2 (0) | ND |
| Another chemotherapy | 0/15 (0) | 0/15 (0) | ND |
| None | 0/14 (0) | 0/14 (0) | ND |
| Number of days between last hematological therapy and COVID‐19 diagnosis in patients with progression, median; mean (range) | 11; 17 (0–98) | ND | |
Abbreviations: AL, acute leukemia; BV‐CHP, Brentuximab Vedotin + Cyclophosphamide + Doxorubicin + Prednisone; COVID‐19, coronavirus disease 2019; CP, convalescent plasma; DRD, Daratumumab + Revlimid + Dexamethasone; ND, not done; NmAbs, neutralizing monoclonal antibodies; RD, Revlimid + Dexamethasone; SCT, stem cell transplantation; VTD, Bortezomib + Thalidomide + Dexamethasone.